

Cytosorbents Corp  
Form 8-K  
August 23, 2013

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): August 21, 2013

**CYTOSORBENTS CORPORATION**

(Exact name of registrant as specified in its charter)

**Nevada**                              **000-51038 98-0373793**  
(State or other jurisdiction of (Commission (IRS Employer

incorporation)                      File Number) Identification No.)

**7 Deer Park Drive, Suite K**

**Monmouth Junction, New Jersey 08852**

(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: **(732) 329-8885**

N/A

Edgar Filing: Cytosorbents Corp - Form 8-K

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On August 21, 2013, CytoSorbents Corporation (the “Company”) held a conference call to discuss Company updates and its financial information for the quarterly period ended June 30, 2013. A copy of the transcript of the conference call is included as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

**Exhibit No. Description**

99.1 Transcript from August 21, 2013 Conference Call (filed herewith).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CYTOSORBENTS  
CORPORATION**

Date: August 23, 2013 By: /s/ Dr. Phillip P. Chan  
Dr. Phillip P. Chan

President and CEO